tiprankstipranks
BioNTech SE (GB:0A3M)
LSE:0A3M

BioNTech SE (0A3M) Share Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

0A3M Analyst Ratings

Moderate Buy
13Ratings
5 Buy
7 Hold
1 Sell
Based on 13 analysts giving stock ratings to
BioNTech
SE
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0A3M Stock 12 Months Forecast

Average Price Target

$111.64
▲(19.93% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $111.64 with a high forecast of $171.00 and a low forecast of $90.00. The average price target represents a 19.93% change from the last price of $93.09.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"89":"$89","172":"$172","109.75":"$109.8","130.5":"$130.5","151.25":"$151.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":171,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$171.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$111.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[89,109.75,130.5,151.25,172],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.153,97.29507692307693,103.43715384615385,109.57923076923078,115.7213076923077,121.86338461538462,128.00546153846153,134.14753846153846,140.2896153846154,146.43169230769232,152.57376923076924,158.71584615384614,164.8579230769231,{"y":171,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.153,92.72892307692308,94.30484615384616,95.88076923076923,97.45669230769231,99.03261538461538,100.60853846153847,102.18446153846153,103.76038461538462,105.3363076923077,106.91223076923077,108.48815384615385,110.06407692307693,{"y":111.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.153,91.0643076923077,90.9756153846154,90.88692307692308,90.79823076923077,90.70953846153847,90.62084615384616,90.53215384615385,90.44346153846153,90.35476923076924,90.26607692307692,90.17738461538461,90.08869230769231,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":127.39,"date":1679616000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.015,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.547,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.16,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.24,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.515,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.515,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.79,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.64,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.115,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":111.713,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":92.59,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":91.153,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$171.00Average Price Target$111.64Lowest Price Target$90.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright
$107.00
Buy
14.94%
Upside
Reiterated
02/12/24
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Molina Healthcare (MOH)
Morgan Stanley
$109.00
Hold
17.09%
Upside
Reiterated
02/02/24
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (NASDAQ: BNTX) and Cardinal Health (NYSE: CAH)
Oppenheimer
Hold
Initiated
01/05/24
BioNTech initiated with a Perform at OppenheimerBioNTech initiated with a Perform at Oppenheimer
HSBC
$111.00
Hold
19.24%
Upside
Downgraded
10/16/23
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alignment Healthcare (NASDAQ: ALHC) and BioNTech SE (NASDAQ: BNTX)
Argus Research
$203.00
Buy
118.07%
Upside
Reiterated
06/16/23
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), BioNTech SE (NASDAQ: BNTX) and Sarepta Therapeutics (NASDAQ: SRPT)

Best Analysts Covering BioNTech SE

Which Analyst Should I Follow If I Want to Buy GB:0A3M and Sell After:
1 Month
Tazeen AhmadBank of America Securities
Success Rate
7/12 ratings generated profit
58%
Average Return
-0.07%
reiterated a buy rating 9 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of -0.07% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Zhiqiang ShuBerenberg Bank
Success Rate
12/23 ratings generated profit
52%
Average Return
+4.37%
reiterated a buy rating 11 months ago
Copying Zhiqiang Shu's trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +4.37% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Tazeen AhmadBank of America Securities
Success Rate
4/12 ratings generated profit
33%
Average Return
+23.08%
reiterated a buy rating 9 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +23.08% per trade.
2 Years
Tazeen AhmadBank of America Securities
Success Rate
4/12 ratings generated profit
33%
Average Return
+36.42%
reiterated a buy rating 9 days ago
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +36.42% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A3M Analyst Recommendation Trends

Rating
Nov 23
Dec 23
Jan 24
Feb 24
Mar 24
Strong Buy
10
10
3
3
4
Buy
5
7
9
8
8
Hold
11
12
12
10
12
Sell
0
1
1
1
1
Strong Sell
0
0
0
0
0
total
26
30
25
22
25
In the current month, 0A3M has received 12 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. 0A3M average Analyst price target in the past 3 months is $111.64.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0A3M Financial Forecast

0A3M Earnings Forecast

Next quarter’s earnings estimate for 0A3M is -$0.95 with a range of -$2.98 to $1.00. The previous quarter’s EPS was $2.06. 0A3M beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 34.62% of the time in the same period. In the last calendar year 0A3M has Outperformed its overall industry.
Next quarter’s earnings estimate for 0A3M is -$0.95 with a range of -$2.98 to $1.00. The previous quarter’s EPS was $2.06. 0A3M beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 34.62% of the time in the same period. In the last calendar year 0A3M has Outperformed its overall industry.

0A3M Sales Forecast

Next quarter’s sales forecast for 0A3M is $538.69M with a range of $173.88M to $1.36B. The previous quarter’s sales results were $1.59B. 0A3M beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.34% of the time in the same period. In the last calendar year 0A3M has Outperformed its overall industry.
Next quarter’s sales forecast for 0A3M is $538.69M with a range of $173.88M to $1.36B. The previous quarter’s sales results were $1.59B. 0A3M beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.34% of the time in the same period. In the last calendar year 0A3M has Outperformed its overall industry.

0A3M Stock Forecast FAQ

What is GB:0A3M’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is $111.64.
    What is GB:0A3M’s upside potential, based on the analysts’ average price target?
    BioNTech SE has 19.93% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioNTech SE a Buy, Sell or Hold?
          BioNTech SE has a conensus rating of Moderate Buy, which is based on 5 buy ratings, 7 hold ratings and 1 sell ratings.
            What is BioNTech SE’s share price target?
            The average share price target for BioNTech SE is $111.64. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $171.00 ,and the lowest forecast is $90.00. The average share price target represents 19.93% Increase from the current price of $93.09.
              What do analysts say about BioNTech SE?
              BioNTech SE’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of BioNTech SE?
                To buy shares of GB:0A3M, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis